Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmasset Inc.

Division of Gilead Sciences Inc.
www.pharmasset.com

Latest From Pharmasset Inc.

Why Deals Fail: The Reasons May Be Clinical, Economic Or Strategic

Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Looking back at significantly sized acquisitions over just five years reveals that half of 2014’s acquisitions can already be judged as outright failures or, at best, questionable. But some lessons can be learned from dud deals.

Business Strategies Deals

Gilead Increasingly Seems Focused On Combo Therapy In NASH

At EASL, Gilead indicated it may not take any of its current NASH candidates forward as monotherapy options. Trial collaboration with Novo Nordisk may suggest pessimism toward selonsertib after Phase III disappointment.

Commercial Clinical Trials

MPM Raises $400m To Build Early-Stage Biotechs

The venture capitalist builds biotechs from scratch and with this latest fund, MPM is looking to add to its sector-leading record of 49 FDA-approved drugs and over 100 IPOs and acquisitions.

Financing ImmunoOncology

Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom

Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Gilead Sciences Inc.
  • Senior Management
  • P. Schaefer Price, CEO
    Kurt Leutzinger, CFO
    Abel De La Rosa, PhD, SVP, Bus. Dev. & Scientific Affairs
    Michael J Otto, PhD, CSO
    Patrick T Higgins, EVP, Mktg. & Sales
  • Contact Info
  • Pharmasset Inc.
    Phone: (609) 613-4100
    303-A College Rd. E.
    Princeton, NJ 08540
    USA
UsernamePublicRestriction

Register